Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionVTSMX - Vanguard Total Stock Market Index Fund Investor Shares
Latest Disclosed Ownership3,711,365 shares
Latest Disclosed Value $ 91,893,397
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares reports 1.18% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - VTSMX - Vanguard Total Stock Market Index Fund Investor Shares filed a NPORT-P form disclosing ownership of 3,711,365 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $91,893,397 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 3,668,031 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 1.18% during the quarter. The current value of the position is $116,870,884 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP CATALYST PHARMAC EC US14888U1016 3,711,365 43,334 1.18 91,893 7.34 0.0046
2026-02-26 2025-12-31 NP CATALYST PHARMAC EC US14888U1016 3,668,031 23,033 0.63 85,612 19.23 0.0042
2025-11-25 2025-09-30 NP CATALYST PHARMAC EC US14888U1016 3,644,998 -63,644 -1.72 71,806 -10.77 0.0036
2025-08-27 2025-06-30 NP CATALYST PHARMAC EC US14888U1016 3,708,642 132,012 3.69 80,478 -7.21 0.0042
2025-05-28 2025-03-31 NP CATALYST PHARMAC EC US14888U1016 3,576,630 53,803 1.53 86,733 17.97 0.0051
2025-02-28 2024-12-31 NP CATALYST PHARMAC EC US14888U1016 3,522,827 -32,426 -0.91 73,521 4.02 0.0041
2024-11-26 2024-09-30 NP CATALYST PHARMAC EC US14888U1016 3,555,253 6,060 0.17 70,678 28.56 0.0040
2024-08-27 2024-06-30 NP CATALYST PHARMAC EC US14888U1016 3,549,193 62,293 1.79 54,977 -1.09 0.0033
2024-05-29 2024-03-31 NP CATALYST PHARMAC EC US14888U1016 3,486,900 341,912 10.87 55,581 5.13 0.0035
2024-02-29 2023-12-31 NP CATALYST PHARMAC EC US14888U1016 3,144,988 17,641 0.56 52,867 44.61 0.0036
2023-11-28 2023-09-30 NP CATALYST PHARMAC EC US14888U1016 3,127,347 58,431 1.90 36,559 -11.37 0.0028
2023-08-28 2023-06-30 NP CATALYST PHARMAC EC US14888U1016 3,068,916 800 0.03 41,246 -18.92 0.0030
2023-05-26 2023-03-31 NP CATALYST PHARMAC EC US14888U1016 3,068,116 47,631 1.58 50,869 -9.46 0.0041
2023-03-01 2022-12-31 NP CATALYST PHARMAC EC US14888U1016 3,020,485 309,517 11.42 56,181 61.53 0.0049
2022-11-29 2022-09-30 NP CATALYST PHARMAC EC US14888U1016 2,710,968 855 0.03 34,782 83.09 0.0033
2022-08-29 2022-06-30 NP CATALYST PHARMAC EC US14888U1016 2,710,113 49,325 1.85 18,998 -13.87 0.0017
2022-05-31 2022-03-31 NP CATALYST PHARMAC EC US14888U1016 2,660,788 -81,120 -2.96 22,058 18.83 0.0017
2022-03-01 2021-12-31 NP CATALYST PHARMAC EC US14888U1016 2,741,908 -114,807 -4.02 18,563 22.60 0.0014
2021-11-29 2021-09-30 NP CATALYST PHARMAC EC US14888U1016 2,856,715 2,081 0.07 15,141 -7.76 0.0012
2021-08-30 2021-06-30 NP CATALYST PHARMAC EC US14888U1016 2,854,634 -123,367 -4.14 16,414 19.57 0.0013
2021-06-01 2021-03-31 NP CATALYST PHARMAC EC US14888U1016 2,978,001 -317,430 -9.63 13,729 24.73 0.0012
2021-03-01 2020-12-31 NP CATALYST PHARMAC EC US14888U1016 3,295,431 533,014 19.30 11,007 34.15 0.0010
2020-11-27 2020-09-30 NP CATALYST PHARMAC EC US14888U1016 2,762,417 0 0.00 8,204 -35.72 0.0009
2020-08-31 2020-06-30 NP CATALYST PHARMAC EC US14888U1016 2,762,417 -171,360 -5.84 12,762 12.99 0.0015
2020-06-01 2020-03-31 NP CATALYST PHARMAC EC US14888U1016 2,933,777 209,720 7.70 11,295 10.57 0.0015
2020-02-28 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 2,724,057 -70,350 -2.52 10,215 -31.16 0.0011
2019-11-29 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,794,407 2,794,407 14,838 0.0018
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.